CORRECTING and REPLACING NitroMed to Announce Fourth Quarter and Year End 2007 Earnings in February 14th Call and Webcast
NitroMed zu myNews hinzufügen Was ist das?
In the section titled "Webcast Access:", second sentence, the hyperlink
http://www.navg.com/Navigators/PressReleases.aspx?id=2862 should read
www.theconferencingservice.com/prereg/key.process?key=PLEL4CJH4.
The corrected release reads:
NITROMED TO ANNOUNCE FOURTH QUARTER AND YEAR END 2007 EARNINGS IN
FEBRUARY 14TH CALL AND WEBCAST NitroMed, Inc.
(NASDAQ: NTMD) announced today that it will host a webcast and
conference call to discuss Company financial results for its fourth
quarter and year ended December 31, 2007.
Event Date: Thursday, February 14th, 2008
Event Time: 9:00 AM Eastern Time
Dial-in Access Numbers:
Domestic: 888-713-4218
International: 617-213-4870
Participant passcode: 19159371
Webcast Access:
Go to www.nitromed.com.
Participants may register in advance at www.theconferencingservice.com/prereg/key.process?key=PLEL4CJH4.
An audio replay of this event, available by two hours after the call,
can be accessed by dialing 888-286-8010 (domestic) or 617-801-6888
(international). The replay passcode ID for all callers is 26064795. An
audio webcast of this event will be archived on NitroMed’s
website for an indefinite period of time.
About NitroMed, Inc.
NitroMed of Lexington, Massachusetts is an emerging pharmaceutical
company and the maker of BiDil®
(isosorbide dinitrate/hydralazine hydrochloride), an orally administered
medicine available in the United States for the treatment of heart
failure in self-identified black patients. In this population, BiDil is
indicated as an adjunct to current standard therapies such as
angiotensin converting enzyme (ACE) inhibitors and/or beta blockers.
There is little experience in patients with New York Heart Association
Class IV heart failure. BiDil was approved by the U.S. Food and Drug
Administration, primarily on the basis of efficacy data from the Company’s
landmark A-HeFT (African American Heart Failure Trial) clinical study,
and is marketed by NitroMed through a specialty medicines sales
organization.
For full prescribing information, visit: www.BiDil.com.
BiDil is a registered trademark of NitroMed, Inc.
